eli lilly retatrutide lawsuit Lilly's experimental obesity drug is not available to the public., But exclusive reporting from our editorial partners at @statnews found that this spring the FDA allowed one person -- Eli Lilly touts strong results

Description

Most patients experience minimal discomfort

We dont expect to lose zero muscle when we lose weight, says Dr

Likewise, the FDCAs list of prohibited acts states simply that the misbranding of any drug is a prohibited act.[3] The Advertisement does not comply with the FDCA because the Advertisement misbrands drugs, and it is a violation of the FDCA to misbrand a drug, to introduce a misbranded drug into interstate commerce, and to deliver a misbranded drug for introduction into interstate commerce.[4] The FDCA also provides that prescription drug advertising for any prescription drug distributed or offered for sale must contain a true statement of information in brief summary relating to the side effects, contraindications, and effectiveness of a drug.[5] The FDCA and FDA regulations also require that prescription drug television advertisements provide a major statement relating to side effects and contraindications in a clear, conspicuous, and neutral manner.[6] The FDCA and FDA regulations do not exempt compounded drug advertisements from such requirements, and the Advertisement did not provide this required information to consumers.[7] It is also a violation of the FDCA to disseminate a television advertisement without complying with the FDAs requirements for television advertisements.[8] The FDCA and FDA regulations provide for the submission of television advertisements for a drug to the FDA for review before the television advertisement is disseminated, and compounded drugs are drugs under the FDCA.[9] The FDCAs section on pharmacy compounding sets forth specific sections of the FDCA that do not apply to compounded drug products

Rahmanian views the timing as critical, citing a post-pandemic cultural movement toward health and the recent availability of GLP-1s in both injectable and oral forms